2002
DOI: 10.1182/blood.v100.5.1765.h81702001765_1765_1773
|View full text |Cite
|
Sign up to set email alerts
|

Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects

Abstract: Rituximab, a chimeric human immunoglobulin G1(IgG1) anti-CD20 monoclonal antibody has been shown to mediate cytotoxicity in malignant B cells via several mechanisms in vitro. These include direct antiproliferative and apoptotic effects, complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated cytotoxicity (ADCC). Glucocorticoids (GCs) are often administered in conjunction with rituximab in chemotherapeutic regimens or as premedication to reduce infusion-related symptoms. The effects of GCs… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
25
1
3

Year Published

2004
2004
2015
2015

Publication Types

Select...
5
1
1

Relationship

0
7

Authors

Journals

citations
Cited by 117 publications
(32 citation statements)
references
References 33 publications
3
25
1
3
Order By: Relevance
“…3; Tables S1 and S2, and Figs. S1-S4), which is in consistent with the results of previous studies (maximum inhibition was about 30-70%) [12][13][14][15].…”
Section: Discussionsupporting
confidence: 92%
See 1 more Smart Citation
“…3; Tables S1 and S2, and Figs. S1-S4), which is in consistent with the results of previous studies (maximum inhibition was about 30-70%) [12][13][14][15].…”
Section: Discussionsupporting
confidence: 92%
“…The findings on dose-dependent comparison of anti-cell proliferation activities of BM-ca, rituximab, ofatumumab, and infliximab are depicted in Figure 3. In accordance with previously reported results [12][13][14][15], no complete inhibition of cell proliferation by the anti-CD20 antibodies was observed in either RC-K8 or SU-DHL-4 cells. However, efficacies of these antibodies were largely different.…”
Section: Anti-cell Proliferation Activity Of Anti-cd20 Antibodies In supporting
confidence: 93%
“…Temporary B‐cell depletion occurs but is not associated with immunodeficiency. The addition of dexamethasone to rituximab leads to a supra‐additive cytotoxicity with respect to its direct antiproliferative and apoptotic effects 2 …”
mentioning
confidence: 99%
“…Esses anticorpos anti-CD20 provaram-se capazes de induzir apoptose de células-B tumorais humanas assegurando assim sua capacidade fármaco-terapêutica [5,[7][8][9][10][11][12][13].…”
Section: Tabela 3 Antígenos Comuns Das Células-b De Lnh E Seus Anticunclassified
“…As células-B dos LNH são ideais para essa modalidade de tratamento por sua acessibilidade para os anticorpos terapêuticos, sensibilidade ao mecanismo de morte Rituximab, anticorpo anti-CD20 quimérico, específico para o antígeno CD20, Contudo, este fato salientou a importância e necessidade de uma nova abordagem de tratamento com garantias reais de alívio aos portadores desse tipo de neoplasia, a Radioimunoterapia (RIT) [9,11,12,18,19]. Radioimunoterapia é uma nova promessa de tratamento para portadores de LNH de células-B refratários ou quimioterapia recorrentes.…”
Section: Tabela 3 Antígenos Comuns Das Células-b De Lnh E Seus Anticunclassified